In HPV-associated cervical cancer, combining ferroptosis inhibitors such as GPX4 with conventional chemotherapy, or employing ferroptosis inducers alongside chemotherapeutic drugs like cisplatin, as well as targeting the KRAS/Nrf2/SLC7A11 signaling axis, may help overcome ferroptosis resistance and restore susceptibility to ferroptosis. Here, GPX4 is linked to cervical carcinoma.